JENKEM(SH:688356) 智通财经网·2026-02-27 11:19Core Viewpoint - The company reported significant growth in both revenue and net profit for the fiscal year 2025, driven primarily by strong performance in overseas markets [1] Financial Performance - The company achieved total operating revenue of 316.085 million yuan, representing a year-on-year increase of 39.19% [1] - The net profit attributable to the parent company was 63.3935 million yuan, reflecting a year-on-year growth of 112.46% [1] Business Drivers - The growth in revenue and profit was largely attributed to a notable increase in overseas business [1] - Sales of new drug products from overseas clients continued to expand significantly after their market launch, leading to substantial revenue from related orders [1] - The order volume from the company's largest overseas medical device client increased significantly compared to the same period last year, contributing to steady growth in overseas medical device sales revenue [1]